Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, open-label, non-randomized, multi-center, dose escalation study of olaparib in combination with eribulin mesylate to assess the safety, tolerability, and efficacy in patients with recurrent or metastatic triple-negative-type breast cancer, who have received anthracycline and taxane agents

Next Previous
Trial Profile

A Phase I/II, open-label, non-randomized, multi-center, dose escalation study of olaparib in combination with eribulin mesylate to assess the safety, tolerability, and efficacy in patients with recurrent or metastatic triple-negative-type breast cancer, who have received anthracycline and taxane agents

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 28 Jan 2019 Results assessing efficcay and safety published in the European Journal of Cancer.
  • 05 Mar 2018 Status changed from active, no longer recruiting to completed.
  • 12 Sep 2017 Primary endpoint has been met. (Phase II: tumor response rate (RR)) as per results presented at the 42nd European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top